Business Wire

Quidel’s Lyra® Direct SARS-CoV-2 Assay Receives Emergency Use Authorization and CE Mark for Molecular Detection of COVID-19, Without Extraction Step

SAN DIEGO--(BUSINESS WIRE)--Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced ...

DiaSorin S.p.A. (DIA): 2025 Product Pipeline and Strategy Analysis Report

The "DiaSorin S.p.A. (DIA) - Product Pipeline Analysis, 2025 Update" has been added to ResearchAndMarkets.com's offering. DiaSorin's immunodiagnostic and molecular diagnostics offerings are integral ...
Labroots

Keynote Presentation: Integration of the Simplexa C. difficile Direct assay into a two-step algorithm for the laboratory diagnosis of C. difficile

Clostridium difficile infection (CDI) has become the leading cause of healthcare associated infections in the United States and currently accounts for 15% to 20% of infectious diarrhea in the ...
Nasdaq

University of Paris Researchers Utilize Fluidigm Mass Cytometry and Maxpar Direct Immune Profiling Assay to Identify Distinct Phenotype among Patients with Severe COVID-19

SOUTH SAN FRANCISCO, Calif., May 19, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health ...
Business Wire

Quidel’s Lyra® Direct SARS-CoV-2 Assay Submitted for Emergency Use Authorization for Molecular Detection of COVID-19, Without Extraction Step

Quidel is manufacturing approximately 500,000 tests per week and has begun shipping the improved product to its customers. The assay is currently available for sale in the United States while under ...